RBR-9k66x6
Recruiting
未知
Everolimo in combination with Tacrolimus low doses versus Mycophenolate Sodium gastro-resistant coated tablets with low doses of Tacrolimus in Liver Transplant recipients de novo”
Conditionsiver transplantation immunossupression, hepatic graft rejection and loss, receptor death, immunosuppressive drug myelotoxicity, posttransplant diabetes mellitus, posttransplant dyslipidemia, cytomegalovirus events, hepatic artery thrombosis, bile duct complications, operative wound complications, incisional hernia, postoperative kidney failure, proteinuria, discontinuation of the immunosuppressive regimen.Liver transplantationeverolimustacrolimusmycophenolate sodium.E04.210.650D02.540.505.810D02.540.505.760.500D02.241.081.193.678
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- iver transplantation immunossupression, hepatic graft rejection and loss, receptor death, immunosuppressive drug myelotoxicity, posttransplant diabetes mellitus, posttransplant dyslipidemia, cytomegalovirus events, hepatic artery thrombosis, bile duct complications, operative wound complications, incisional hernia, postoperative kidney failure, proteinuria, discontinuation of the immunosuppressive regimen.Liver transplantation
- Sponsor
- Hospital Geral de Fortaleza
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Orthotopic whole organ liver transplant recipients; deceased donor; age above 18 years; both sexes; with graft functionality within 72h of reperfusion.
Exclusion Criteria
- •Patients with pre\-transplant protein and urinary creatinine ratio greater than 1mg / g or proteinuria 24h greater than 1g; multiple organ transplant recipients; patients with hypercholesterolemia (greater than 350 mg / dL) or hypertriglyceridemia (greater than 500 mg / dL) severe if use of lipid\-lowering therapy with controlled hyperlipidemia will be accepted; previously transplanted liver patients who progressed with graft loss and in need of retransplantation; patients with positive serology for HIV; women who are pregnant, who are planning to become pregnant, are pregnant or breastfeeding, or do not agree to use effective methods of contraception; patients with difficult decision making who are not judged medically or mentally capable of providing informed consent on their own.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A low-dose immunosuppression protocol in lung transplantatioung TransplantationTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]EUCTR2018-001680-24-ATMedical University of Vienna - Abteilung für Thoraxchirurgie110
Completed
Phase 4
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal TransplantTransplantation InfectionCytomegalovirus InfectionsNCT02084446Ronaldo de Matos Esmeraldo, MD120
Unknown
Phase 4
Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft RecipientsKidney; Complications, AllograftNCT02036554Seoul St. Mary's Hospital234
Recruiting
Not Applicable
Management of the combination of tacrolimus with azoles: effect of tacrolimus formulation on drug-drug interaction magnitudeMycoses due to opportunistic pathogensfungal infection in patients with immune deficiencies who would otherwise not be infected10017528NL-OMON54925niversitair Medisch Centrum Groningen24
Completed
Phase 4
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant RecipientsLiver TransplantationNCT01551212Novartis Pharmaceuticals339